Rozel R. Tumaneng Prof. Simonnette B.

Leoncio
BSN 3B2 NCM 101

Gene treatment for chemo-resistant metastatic pancreatic, breast,

colon, melanoma cancers 
FDA GRANTS "ORPHAN" STATUS
PHILLIPINES APPROVE IMMEDIATE USE
(RobertsReview, RI, USA) -- Human clinical results reported in the International Journal of
Oncology reveal 83% of patients with chemo-resistant metastatic pancreatic cancer tumors
who received Rexin-G, a new gene therapy, showed impressive tumor reduction or tumor
death!

In a second study, 64% tumor response was observed in patients with metastatic breast cancer
as well as colon cancer, uterine cancer, muscle and vocal cord cancers, as well as malignant
melanoma. In a third study, where optimally adjusted doses of Rexin-G were administered to
three patients, tumor reduction and/or necrosis was achieved in all three patients.

The dramatic functionality of this, the world's first cancer targeted gene delivery system is
profound.  The treatment appears to offer broad spectrum activity in many treatment-resistant
tumor types, and, equally important, the treatment appears to be exceptionally safe and easily
tolerated by patients.

Lack of toxicity, dramatic tumor reduction, and the enhanced quality-of-life experienced by
patients receiving Rexin-G during Phase I/II FDA approved trials, constitute meaningful clinical
benefits that underscore the need for expediting development and testing of Rexin-G for
pancreatic cancer patients, and, potentially, for all solid tumor patients.  The FDA has already
taken note of these first human test results and has moved to speed the process of testing and
marketing.

Dr. Frederick L. Hall, President and CEO of Epeius Biotechnologies, helped develop the
remarkable mew treatment said, "Whereas logistics had previously stymied delivery of genetic
medicine to target lesions (tumors) within the body, intravenous infusions of Rexin-G
(succeeded and) has stymied intractable cancers without collateral damage to normal organs." 

The results compiled in these pioneering early  studies, already have convinced the U.S. FDA to
grant Rexin-G "orphan drug" status for treatment of pancreatic cancer, and subsequently, to
provide federal support to speed up and continue clinical trials using Rexin-G in the United
States.  Other countires aren't waiting:

Based on the dramatic new results, the Philippine Bureau of Food and Drugs aren't waiting. 
They already have granted Rexin-G approval for use in treating all chemo-resistant tumor types
in the Phillipines.
Reaction:
Nowadays, many diseases, especially cancer are popping due to the exposure to
carcinogens. As the world gets more and more advanced, the risk of people having diseases
also increases. It is good to know that as the world gets complicated, at least people also
become more intelligent which yields to the discovery of different treatments for those
diseases.

The article that I have chosen is entitled “Gene treatment for chemo-resistant
metastatic pancreatic, breast, colon, melanoma cancers”. I picked this article, first because this
is already approved in the Philippines. Being a citizen of the country and a medical practitioner
as well, it would be a great help to know the different available treatments in the country.
Secondly, it’s because when they conducted an experiment to three patients, the Rexin-G is
effective to three patients. The tumor ceased and its toxicity is less compared to other
therapies and it is more tolerable and safer for the patients. One more thing is, as written in the
title, it is effective not only for breast cancer but so with colon cancer, uterine cancer, muscle
and vocal cord cancers, pancreatic cancers and malignant melanoma.

It was very ________ that the Philippines is already using this kind of treatment but the
problem is, not all Filipinos can use this. Same as with any other therapies, this kind of
treatment can only be given who can afford it. Therefore, even though it is effective, l….